 PARK CITY, Utah--BUSINESS WIRE--- ARNA--Arena Pharmaceuticals, Inc. Nasdaq: ARNA today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate S1P receptor modulator, for the treatment of eosinophilic esophagitis EoE. Etrasimod is being investigated in the Phase 2b VOYAGE trial, a randomized, double-blind, placebo-controlled trial, with a primary efficacy measurement at week 